Semaglutide results: what clinical trials and real-world use tell us

What did the STEP 1 trial find, and does the 15% figure apply to everyone?

The 15% average from STEP 1 is a population mean, not a promise. In the same trial, roughly a third of participants on semaglutide 2.4mg lost 20% or more of their starting weight, while a smaller group lost less than 5%. Biology, starting weight, adherence to dietary changes and how well the medicine is tolerated across the titration schedule all pull the final number in different directions.

It is also worth understanding what the trial measured: 68 weeks of treatment, with participants attending regular support sessions on diet and physical activity. The medicine was one part of the picture, not the whole of it. People who kept up with the lifestyle component tended to see better outcomes, which is reflected in the trial's own secondary analyses.

For a closer look at how weight loss unfolds week by week, the semaglutide weight-loss results page maps out what the data shows at each stage of treatment, from early weeks through to the maintenance phase. Early on, many people find the scale barely moves, that is normal. The titration period, when doses step up to manage tolerability, is not when the bulk of weight loss happens.

The NICE appraisal of semaglutide (TA875) reviewed this evidence and recommended the medicine within specialist weight management services for eligible adults, noting the clinical meaningfulness of the weight reductions observed.

How quickly do semaglutide results appear?

Most people do not notice significant weight loss in the first two or three weeks. The starting dose (0.25mg) is a tolerability step. Its job is to let your body adjust to the medicine before doses increase, not to produce rapid loss. Clinically meaningful weight change tends to become visible from around week four onwards for many people, picking up speed as doses step toward the 2.4mg maintenance level.

Our page on how long Wegovy takes to work covers this timeline in detail. The short version: patience in the early weeks is not a sign something is wrong. The appetite-suppressing effect of semaglutide builds as the dose increases, and the cumulative reduction in calorie intake over months is what drives the outcome.

Timing matters in practical ways too. Patients who start just before a holiday or a period of disruption sometimes find the early adjustment phase harder to manage, not because results are worse, but because routines that support the medicine are harder to maintain. Starting when you can keep a stable weekly schedule gives the titration the best conditions to work.

If you want a granular sense of the early weeks, the week-one picture and the changes reported at week four are covered separately.

What influences whether someone gets the best results from semaglutide?

The trial evidence points to a few consistent patterns. Adherence to the full titration schedule matters: people who tolerate dose increases and reach 2.4mg tend to lose more weight than those who stay at lower maintenance doses due to side effects. Diet remains relevant, semaglutide reduces appetite, but it does not override a consistently high-calorie intake. Protein adequacy and staying hydrated help manage both side effects and muscle preservation.

Physical activity adds to the outcome. The STEP 1 participants had structured lifestyle support, which is one reason real-world results sometimes differ from trial averages. The gap is not a flaw in the medicine; it reflects how much the surrounding behaviour contributes.

Starting weight also plays a role: people with higher baseline BMI often see larger absolute kilogram losses, while percentage losses can be broadly similar across BMI ranges. NICE and NHS England both note that for semaglutide, a prescriber reviews progress at six months, if weight loss is less than 5% at the maintenance dose, continuing on clinical grounds is reassessed. That threshold is in TA875 and is part of responsible prescribing, not a reason to avoid starting treatment.

For a broader view of how semaglutide sits alongside other licensed weight-loss options, the weight-loss treatments overview sets out the landscape clearly.

What happens to results when treatment stops?

This is the question our prescribers hear most often, and it deserves a straight answer: the evidence consistently shows that most of the lost weight returns after stopping semaglutide. The STEP 4 extension trial found that participants who stopped semaglutide after 68 weeks regained an average of around two-thirds of their prior loss within a year, while those who continued maintained their reduction.

That pattern reflects the biology of obesity, not a failure of willpower. Semaglutide works partly by correcting an underlying hormonal environment that drives appetite higher than it should be. Remove the medicine and that environment reasserts itself. This is why long-term clinical supervision, regular review and honest conversations with your prescriber about duration matter as much as the starting results, and if you are wondering how long a bottle of semaglutide lasts as you plan ahead, that is covered in detail on its own page.

It also explains why NICE's recommendation for semaglutide (TA875) specifies use within a specialist weight management service with multidisciplinary support, for a maximum of two years under NHS commissioning. Private treatment through a regulated pharmacy operates outside those NHS time limits, but the clinical logic of ongoing review remains the same. Semaglutide best results over time are sustained results, and those come from a supervised plan rather than an open-ended prescription. If you have questions about your specific situation, the nume FAQs cover common queries, or you can reach the team via our contact page.

Thinking about whether semaglutide might suit you? Check your eligibility with a free consultation, reviewed the same day by a GPhC-registered prescriber.